Deterioro de la función pulmonar en pacientes con Diabetes Mellitus Tipo 2

Abstract

Introduction: The deterioration of lung function in diabetic patients has emerged as a relevant area of research. Increasingly, the influence of Type 2 Diabetes Mellitus on the respiratory system it is becoming more relevant. Therefore, understanding this relationship is crucial to improving these patients’ clinical and therapeutic management. Objective: To describe the deterioration of lung function in patients with type 2 Diabetes Mellitus. Methodology: An exhaustive search of the scientific literature was conducted in databases such as PubMed, Elsevier, and Web of Science, using the health science descriptors (DeCS) 'diabetes mellitus type 2', 'respiratory function,' and 'lung'; such as the English counterparts (MeSH) 'pulmonary function,' 'diabetes mellitus type 2,' and 'lung' using the Boolean operators 'AND' and 'OR, from Spanish and English. Results: Hyperglycemia produces lung conditions, and hypoglycemic drugs can increase their progression. Within studies carried out on diabetics, the majority had a significant decrease in their spirometric indices, indicating the severity of the deterioration of lung function. Liraglutide, metformin, corticosteroids, thiazolidines, AAT augmentation therapy and, spirometric maneuvers are effective for glycemic control and lung function improvement. Conclusions: Glycemic control and deterioration of lung function in patients with type 2 Diabetes Mellitus have a close relationship, given the marked prevalence. Therapeutic interventions serve the purpose of preserving lung function and counteracting hyperglycemia.